Please login to the form below

Not currently logged in

Bodnar pleads guilty in BMS case

Andrew Bodnar, former senior executive of Bristol-Myers Squibb, has pleaded guilty to dishonest dealings relating to a patent deal involving Plavix

Andrew Bodnar, former senior executive of Bristol-Myers Squibb (BMS), has pleaded guilty to dishonest dealings relating to a patent deal involving Plavix. 

In 2006, BMS was negotiating a settlement of litigation with Apotex over the validity of the patent for Plavix. At the time, BMS was subject to a consent decree – for an unrelated matter – requiring the company to submit any proposed patent settlements for review with the Federal Trade Commission (FTC).  

Bodnar reassured Apotex that BMS would not launch a generic version of Plavix if the generics company agreed not to launch a version until 2011. He misled the FTC by claiming that he had not made these representations.

In June 2007, BMS agreed to plead guilty and pay a $1m fine. The US Department of Justice said that BMS had tried to block competition that could have lowered the cost of blood-thinning drugs. 

Scot Hammond, Acting Assistant Attorney General in charge of the Department's anti-trust division said: "Those who attempt to mislead the federal government or undermine the integrity of its functions should expect to face criminal prosecution."

Bodnar could face a year in jail and a fine of up to $100,000 or double the amount of any financial gain derived from his illegal actions.

7th April 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....